HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial
Articolo
Data di Pubblicazione:
2023
Abstract:
In JACOB trial, pertuzumab added to trastuzumab-chemotherapy did not significantly improve survival of patients with HER2-positive metastatic gastric cancer, despite 3.3 months increase versus placebo. HER2 copy number variation (CNV) and AMNESIA panel encompassing primary resistance alterations (KRAS/PIK3CA/MET mutations, KRAS/EGFR/MET amplifications) may improve patients' selection for HER2 inhibition.
Tipologia CRIS:
03A-Articolo su Rivista
Elenco autori:
Pietrantonio, Filippo; Manca, Paolo; Bellomo, Sara Erika; Corso, Simona; Raimondi, Alessandra; Berrino, Enrico; Morano, Federica; Migliore, Cristina; Niger, Monica; Castagnoli, Lorenzo; Pupa, Serenella Maria; Marchio', Caterina; Di Bartolomeo, Maria; Restuccia, Eleonora; Lambertini, Chiara; Tabernero, Josep; Giordano, Silvia
Link alla scheda completa:
Link al Full Text:
Pubblicato in: